Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Pierre Bousset"'
Autor:
Juliette Lambert, Cécile Pautas, Christine Terré, Emmanuel Raffoux, Pascal Turlure, Denis Caillot, Ollivier Legrand, Xavier Thomas, Claude Gardin, Karïn Gogat-Marchant, Stephen D. Rubin, Rebecca J. Benner, Pierre Bousset, Claude Preudhomme, Sylvie Chevret, Herve Dombret, Sylvie Castaigne
Publikováno v:
Haematologica, Vol 104, Iss 1 (2019)
The randomized, phase III ALFA-0701 trial showed that a reduced and fractionated dose of gemtuzumab ozogamicin added to standard front-line chemotherapy significantly improves event-free survival (EFS) in adults with de novo acute myeloid leukemia (A
Externí odkaz:
https://doaj.org/article/43cadb5fe3eb403d946e81a6eda975e0
Autor:
Pau Montesinos, Vamsi Kota, Joseph Brandwein, Pierre Bousset, Rebecca J. Benner, Erik Vandendries, Ying Chen, Mary Frances McMullin
Publikováno v:
Montesinos, P, Kota, V, Brandwein, J, Bousset, P, Benner, R J, Vandendries, E, Chen, Y & McMullin, M F 2023, ' A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia ', Cancer Chemotherapy and Pharmacology . https://doi.org/10.1007/s00280-023-04516-9
Purpose Gemtuzumab ozogamicin (GO) is indicated for treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML). The QT interval, pharmacokinetics (PK), and immunogenicity following the fractionated GO dosing regimen have not been previously
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c04afd875b8e91197e935fe92b6aee1
https://pure.qub.ac.uk/en/publications/286069ea-b2b5-4413-90fd-3d629626116a
https://pure.qub.ac.uk/en/publications/286069ea-b2b5-4413-90fd-3d629626116a
Autor:
Claude Preudhomme, Stephen D. Rubin, Emmanuel Raffoux, Sylvie Castaigne, Sylvie Chevret, Cécile Pautas, Xavier Thomas, Pascal Turlure, Pierre Bousset, Ollivier Legrand, Claude Gardin, Juliette Lambert, Rebecca J. Benner, Christine Terré, Hervé Dombret, Denis Caillot, Karïn Gogat-Marchant
Publikováno v:
Haematologica
Haematologica, Ferrata Storti Foundation, 2019, 104 (1), pp.113-119. ⟨10.3324/haematol.2018.188888⟩
www.haematologica.org/content/104/1/113
Haematologica, 2019, 104 (1), pp.113-119. ⟨10.3324/haematol.2018.188888⟩
Haematologica, Ferrata Storti Foundation, 2019, 104 (1), pp.113-119. ⟨10.3324/haematol.2018.188888⟩
www.haematologica.org/content/104/1/113
Haematologica, 2019, 104 (1), pp.113-119. ⟨10.3324/haematol.2018.188888⟩
The randomized, phase III ALFA-0701 trial showed that a reduced and fractionated dose of gemtuzumab ozogamicin added to standard front-line chemotherapy significantly improves event-free survival (EFS) in adults with de novo acute myeloid leukemia (A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cb677892e09102942f378e3e9613adb
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01984959
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01984959
Autor:
Juliette, Lambert, Cécile, Pautas, Christine, Terré, Emmanuel, Raffoux, Pascal, Turlure, Denis, Caillot, Ollivier, Legrand, Xavier, Thomas, Claude, Gardin, Karïn, Gogat-Marchant, Stephen D, Rubin, Rebecca J, Benner, Pierre, Bousset, Claude, Preudhomme, Sylvie, Chevret, Herve, Dombret, Sylvie, Castaigne
Publikováno v:
Haematologica
The randomized, phase III ALFA-0701 trial showed that a reduced and fractionated dose of gemtuzumab ozogamicin added to standard front-line chemotherapy significantly improves event-free survival (EFS) in adults with de novo acute myeloid leukemia (A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8a570455396af728ca5e6c37b2732b89
https://pubmed.ncbi.nlm.nih.gov/30076173
https://pubmed.ncbi.nlm.nih.gov/30076173